Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial

Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial

Abstract Background This exploratory sub-analysis of the EMPA-HEART CardioLink-6 trial examined whether the previously reported benefit of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin on left ventricular (LV) mass (LVM) regression differs between individuals of South Asian and...

Full description

Bibliographic Details
Main Authors: William Barbour, Erika Wolff, Pankaj Puar, Makoto Hibino, Ehab Bakbak, Aishwarya Krishnaraj, Raj Verma, Meena Verma, Adrian Quan, Andrew T. Yan, Kim A. Connelly, Hwee Teoh, C. David Mazer, Subodh Verma
Format: Article
Language:English
Published: BMC 2023-11-01
Series:BMC Cardiovascular Disorders
Subjects:
Left ventricular mass regression
SGLT2 inhibition
South Asian ethnicity
Coronary artery disease
Type 2 diabetes mellitus
Online Access:https://doi.org/10.1186/s12872-023-03549-5

Internet

https://doi.org/10.1186/s12872-023-03549-5

Similar Items